Mga Batayang Estadistika
| LEI | 529900493806K77LRE72 |
| CIK | 1340243 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MorphoSys AG - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-38455 MorphoSys AG (Exact name of registrant as specified in its charter) |
|
| October 17, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D/A Activist Investment SC 13D/A 1 tm2410988d42sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment no. 6)* MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO GERMANY AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of S |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| October 4, 2024 |
As filed with the Securities and Exchange Commission on October 4, 2024 As filed with the Securities and Exchange Commission on October 4, 2024 Registration No. |
|
| August 29, 2024 |
exhibit991 Half-Year Report JANUARY – JUNE 2024 Contents MorphoSys Group: Half-Year Report January – June 2024 3 Summary 6 Interim Group Management Report 6 Operating Business Performance 11 Strategy and Group Management 11 General Business and Market Environment 12 Intellectual Property 12 Human Resources 12 Financial Analysis 19 Interim Consolidated Financial Statements 19 Consolidated Statement |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files |
|
| August 27, 2024 |
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting Media Release Planegg/Munich, Germany, August 27, 2024 Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company’s Management Board and Supervisory Board at its 2024 Annual General Meeting. |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files |
|
| August 15, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment no. 5)* MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO GERMANY AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 10) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| August 13, 2024 |
Exhibit (a)(5)(M) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Section 23 para. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Persons Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| August 7, 2024 |
Exhibit (a)(5)(L) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| August 5, 2024 |
Page 1 Media Release Planegg/Munich, Germany, August 5, 2024 MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market MorphoSys AG today announced that it has completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its American Depositary Shares (“ADSs”) from the Nasdaq Global Market (“Nasdaq”). |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| August 2, 2024 |
Exhibit (a)(5)(K) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| August 1, 2024 |
Exhibit (a)(5)(J) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 31, 2024 |
Exhibit (a)(5)(I) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| July 30, 2024 |
Exhibit (a)(5)(H) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 29, 2024 |
Exhibit (a)(5)(G) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| July 25, 2024 |
Form 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38455 MorphoSys AG The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Semm |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| July 25, 2024 |
Exhibit (a)(5)(F) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 18, 2024 | ||
| July 18, 2024 |
Exhibit (a)(5)(E) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| July 12, 2024 |
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market Exhibit 99.2 Media Release Planegg/Munich, Germany, July 12, 2024 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) o |
|
| July 12, 2024 |
*** END OF AD HOC ANNOUNCEMENT Exhibit 99.1 Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, July 12, 2024 Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00 MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Novartis BidCo Germany AG submitted a specified request (konkretisiertes Verlangen) to the Morpho |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number: 001-38455 MorphoSys AG (Exact name of registrant as specified in its charter) Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive office |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| July 11, 2024 |
Exhibit (a)(5)(D) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| July 5, 2024 |
Exhibit (a)(5)(C) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Basel, Switzerland Announcement pursuant to Sec. |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Persons Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class of Securities) Ch |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 61776 |
|
| July 5, 2024 |
Exhibit (a)(1)(B) Public Delisting Purchase Offer by Novartis BidCo AG, Basel, Switzerland, to the shareholders of MorphoSys AG, Planegg, Germany Dear Client, On 4 July 2024, Novartis BidCo AG (the “Bidder”) published the Offer Document pursuant to which it offers to all shareholders in MorphoSys AG (“MorphoSys”) to acquire all their shares in MorphoSys (“MorphoSys Shares”) pursuant to a public delisting purchase offer (cash offer, subsequently the “Delisting Purchase Offer”) in the internet at “www. |
|
| July 5, 2024 |
Exhibit (a)(1)(G) This notice is neither an offer to purchase nor a solicitation of an offer to sell any Shares or ADSs (each as defined below). |
|
| July 5, 2024 |
Form W-9 (Rev. March 2024) Request for Taxpayer Identification Number and Certification Department of the Treasury Internal Revenue Service Go to www.irs.gov/FormW9 for instructions and the latest information. Give form to the requester. Do not send to the IRS. Before you begin. For guidance related to the purpose of Form W-9, see Purpose of Form, below. Print or type. See Specific Instructions on |
|
| July 5, 2024 |
Exhibit (a)(1)(C) PUBLIC DELISTING PURCHASE OFFER (CASH OFFER) by Novartis BidCo AG Lichtstrasse 35 4056 Basel Switzerland to the shareholders of MorphoSys AG Semmelweisstr. |
|
| July 5, 2024 |
Exhibit (a)(5)(F) Intranet Post This page is hosted on MorphoSys’ internal intranet, accessible only to MorphoSys employees. |
|
| July 5, 2024 |
Exhibit (d)(1) Delisting Agreement Relating to the Delisting of MorphoSys AG 20 June 2024 DELISTING AGREEMENT The delisting agreement (this “Agreement”) is entered into by and between: 1. |
|
| July 5, 2024 |
Exhibit (a)(2) – Non-binding English Translation – Mandatory Publication pursuant to Sec. |
|
| July 5, 2024 |
Exhibit (a)(1)(E) MORPHOSYS AG Attn: Voluntary Corporate Actions, COY: MPSB P.O. Box 43011 Providence Rhode Island 02940-3011 Information Agent: Georgeson LLC (866)356-7344 LETTER OF TRANSMITTAL TO TENDER AMERICAN DEPOSITARY SHARES OF MORPHOSYS AG Pursuant to the Offer Document dated July 4, 2024, Novartis Bidco AG has commenced a Delisting Purchase Offer to all holders of American Depositary Sha |
|
| July 5, 2024 |
Exhibit (a)(1)(F) NOTICE OF GUARANTEED DELIVERY For Tender of American Depositary Shares (“ADSs”) of MorphoSys AG THE TENDER OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 6:00 P. |
|
| July 5, 2024 |
----------- Client letter (German), end of text ------------------ Exhibit (a)(1)(I) Public Delisting Purchase Offer by Novartis BidCo AG, Basel, Switzerland, to the shareholders of MorphoSys AG, Planegg, Germany Technical specifications for settlement MorphoSys Shares: ISIN DE0006632003 Tendered MorphoSys Shares: ISIN DE000A40ESD9 MorphoSys ADS: ISIN US6177602025 The no-par value bearer shares (Stückaktien) of MorphoSys AG (“MorphoSys”) are evidenced by global certificates eligible for collective custody. |
|
| July 5, 2024 |
Exhibit (a)(1)(D) PUBLIC DELISTING PURCHASE OFFER (CASH OFFER) by Novartis BidCo AG Lichtstrasse 35 4056 Basel Switzerland to the shareholders of MorphoSys AG Semmelweisstr. |
|
| July 5, 2024 |
Security blockage agreement regarding certain shares in MorphoSys AG dated 27 June 2024 Exhibit (d)(3) Security blockage agreement regarding certain shares in MorphoSys AG dated 27 June 2024 Security blockage agreement between (1) UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, Switzerland - the Depositary Bank - (2) Novartis BidCo Germany AG c/o Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuremberg, Germany - the Shareholder - and (3) Novartis BidCo AG, Lichtstrasse 35, 4056 Bas |
|
| July 5, 2024 |
Exhibit (a)(5)(E) MorphoSys.com Investors Page This page is hosted on MorphoSys’ website, MorphoSys.com, in the “Investors” section of the website. This page is available in both English and German. Website: Title: Acquisition of MorphoSys by Novartis Closed Public Takeover Offer by Novartis: On February 5, 2024, MorphoSys entered into a Business Combination Agreement with Novartis BidCo AG (forme |
|
| July 5, 2024 |
NON-BINDING ENGLISH TRANSLATION TABLE OF CONTENTS Exhibit (a)(1)(A) NON-BINDING ENGLISH TRANSLATION Mandatory publication pursuant to Sec. |
|
| July 5, 2024 |
Exhibit 107 Calculation of Filing Fee Table Schedule TO-T (Rule 14d-100) MorphoSys AG (Name of Subject Company) Novartis AG (Offeror – Name of Filing Person) Table 1-Transaction Valuation Transaction Valuation* Fee Rate Amount of Filing Fee** Fees to Be Paid $ 263,898,777 0. |
|
| July 5, 2024 |
Non-tender agreement regarding certain shares in MorphoSys AG dated 26 June 2024 Exhibit (d)(2) Non-tender agreement regarding certain shares in MorphoSys AG dated 26 June 2024 Non-tender agreement between (1) Novartis BidCo Germany AG, Roonstr. |
|
| July 5, 2024 |
Exhibit (d)(4) Version Project Woods Up to EUR 500,000,000 Shareholder Loan Facility Agreement between Novartis BidCo AG (as Lender) and MorphoSys AG (as Borrower) dated June 20, 2024 Hogan Lovells - 2 - TABLE OF CONTENTS Preamble 5 I. |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| July 2, 2024 |
exhibit991 Voting Rights Announcements | 2 July 2024 16:00 MorphoSys AG MorphoSys AG: Correction of a release from 18/04/2024 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| June 21, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment no. 4)* MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO GERMANY AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| June 21, 2024 |
Voting Rights Announcements | 21 June 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 21. |
|
| June 21, 2024 |
Exhibit 9 – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Section 23 para. |
|
| June 20, 2024 |
Exhibit 99.4 All Company Email This email was sent by Arkadius Pichota (MorphoSys’ CEO) to all MorphoSys colleagues after the ad hoc disclosure and press release were distributed. Subject: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out Dear Colleagues, Today, MorphoSys announced that the company has entered into a delisting agreement with Novartis. In |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number: 001-38455 MorphoSys AG (Exact name of registrant as specified in its charter) Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive office |
|
| June 20, 2024 |
Exhibit 99.1 Media Release Planegg/Munich, Germany, June 20, 2024 MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of Mo |
|
| June 20, 2024 |
Exhibit 99.3 Intranet Post This page is hosted on MorphoSys’ internal intranet, accessible only to MorphoSys employees. This page is available in both English and German. Post Title: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out Post Copy: As of June 20, 2024, Novartis holds approximately 91.04% of the total MorphoSys share capital, including purchase |
|
| June 20, 2024 |
Exhibit 99.1 Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, June 20, 2024 Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Novartis BidCo Germany AG informed the MorphoSys A |
|
| June 20, 2024 |
Exhibit 99.1 Media Release Planegg/Munich, Germany, June 20, 2024 MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of Mo |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO-C (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or (13)(e)(1) of the Securities Exchange Act of 1934 MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| June 20, 2024 |
Exhibit 99.2 MorphoSys.com Investors Page This page is hosted on MorphoSys’ website, MorphoSys.com, in the “Investors” section of the website. This page is available in both English and German. Website: Title: Acquisition of MorphoSys by Novartis Closed Business Combination Agreement: On February 5, 2024, MorphoSys entered into a Business Combination Agreement with Novartis BidCo AG (formerly know |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number: 001-38455 MorphoSys AG (Exact name of registrant as specified in its charter) Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive office |
|
| June 20, 2024 |
DELISTING AGREEMENT RELATING TO THE DELISTING MORPHOSYS AG 20 June 2024 Exhibit 99.2 DELISTING AGREEMENT RELATING TO THE DELISTING OF MORPHOSYS AG 20 June 2024 DELISTING AGREEMENT The delisting agreement (this “Agreement”) is entered into by and between: 1. Novartis BidCo AG, a stock corporation (Aktiengesellschaft) incorporated under the Laws of Switzerland, with registered office at Lichtstrasse 35, 4056 Basel, Switzerland, and being registered with the commercial r |
|
| June 20, 2024 |
Exhibit 99.1 - Convenience Translation - Novartis BidCo AG Publication of the decision to launch a public delisting purchase offer (öffentliches Delisting-Erwerbsangebot) in accordance with Sec. 10 para. 1 sentence 1, para. 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) in conjunction with Sec. 39 para. 2 sentence 3 no. 1 of the German Stock |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Person Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class of Securities) Cha |
|
| June 17, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment no. 3)* MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 617760202 (CUSIP Number of Class of Secu |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| June 10, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment no. 2)* MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 617760202 (CUSIP Number of Class of Secu |
|
| June 10, 2024 |
Voting Rights Announcements | 10 June 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| June 10, 2024 |
exhibit991 Voting Rights Announcements | 10 June 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| June 6, 2024 |
Page 1 of 2 Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, June 6, 2024 Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO Following the closing of the takeover offer by Novartis BidCo AG to the shareholders of MorphoSys AG (the “Company”) (FSE: |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| June 5, 2024 |
exhibit991 Voting Rights Announcements | 5 June 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 05. |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 14) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Persons Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| June 4, 2024 |
Exhibit (a)(5)(U) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| June 4, 2024 |
exhibit992 Voting Rights Announcements | 4 June 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 04. |
|
| June 4, 2024 |
exhibit991 Voting Rights Announcements | 4 June 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 04. |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| June 4, 2024 |
exhibit993 Voting Rights Announcements | 4 June 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 04. |
|
| June 4, 2024 |
exhibit994 Voting Rights Announcements | 4 June 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 04. |
|
| May 31, 2024 |
Voting Rights Announcements | 31 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 31. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 29, 2024 |
exhibit993 Voting Rights Announcements | 29 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 29. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 29, 2024 |
exhibit992 Voting Rights Announcements | 29 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 29. |
|
| May 29, 2024 |
exhibit991 Voting Rights Announcements | 29 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 29. |
|
| May 28, 2024 |
exhibit994 Voting Rights Announcements | 27 May 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 27. |
|
| May 28, 2024 |
exhibit995 Voting Rights Announcements | 28 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 28. |
|
| May 28, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment no. 1)* MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 617760202 (CUSIP Number of Class of Secu |
|
| May 28, 2024 |
exhibit991 Voting Rights Announcements | 27 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 27. |
|
| May 28, 2024 |
exhibit993 Voting Rights Announcements | 27 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 27. |
|
| May 28, 2024 |
exhibit992 Voting Rights Announcements | 27 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 27. |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 24, 2024 |
Voting Rights Announcements | 24 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 24. |
|
| May 24, 2024 |
Voting Rights Announcements | 24 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 24. |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 13) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| May 24, 2024 |
Voting Rights Announcements | 24 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 24. |
|
| May 24, 2024 |
Exhibit (a)(5)(T) Notification of Major Holdings This form is for information purpose only. |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 23, 2024 |
Voting Rights Announcements | 23 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 23. |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Persons Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| May 23, 2024 |
Voting Rights Announcements | 22 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. |
|
| May 23, 2024 |
Voting Rights Announcements | 23 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 23. |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 21, 2024 |
exhibit991 Voting Rights Announcements | 21 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 21. |
|
| May 17, 2024 |
Voting Rights Announcements | 17 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 17. |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 17, 2024 |
Voting Rights Announcements | 17 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 17. |
|
| May 16, 2024 |
Voting Rights Announcements | 16 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 16. |
|
| May 16, 2024 |
Voting Rights Announcements | 16 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 16. |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 12) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Persons Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| May 16, 2024 |
Voting Rights Announcements | 16 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 16. |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 16, 2024 |
Exhibit (a)(5)(S) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 15, 2024 |
Voting Rights Announcements | 15 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 15. |
|
| May 15, 2024 |
Voting Rights Announcements | 15 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 15. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 15, 2024 |
Voting Rights Announcements | 15 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 15. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 14, 2024 |
exhibit993 Voting Rights Announcements | 14 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 14. |
|
| May 14, 2024 |
exhibit994 Voting Rights Announcements | 14 May 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 14. |
|
| May 14, 2024 |
exhibit992 Voting Rights Announcements | 14 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 14. |
|
| May 14, 2024 |
exhibit991 Voting Rights Announcements | 14 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 14. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 11) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 13, 2024 |
Voting Rights Announcements | 13 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 13. |
|
| May 13, 2024 |
exhibit992 Voting Rights Announcements | 13 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 13. |
|
| May 13, 2024 |
Exhibit (a)(5)(R) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 10, 2024 |
Voting Rights Announcements | 10 May 2024 16:04 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| May 10, 2024 |
exhibit993 Voting Rights Announcements | 10 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| May 10, 2024 |
Exhibit (a)(5)(Q) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 10, 2024 |
Voting Rights Announcements | 10 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 10) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class o |
|
| May 10, 2024 |
Voting Rights Announcements | 10 May 2024 16:05 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| May 10, 2024 |
Voting Rights Announcements | 10 May 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| May 10, 2024 |
Voting Rights Announcements | 10 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 10. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| May 8, 2024 |
Voting Rights Announcements | 8 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 08. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 8, 2024 |
Voting Rights Announcements | 8 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 08. |
|
| May 8, 2024 |
Exhibit (a)(5)(P) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| May 7, 2024 |
exhibit991 Voting Rights Announcements | 7 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 07. |
|
| May 7, 2024 |
Exhibit (a)(5)(O) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| May 6, 2024 |
Exhibit (a)(5)(N) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 6, 2024 |
Voting Rights Announcements | 6 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 06. |
|
| May 6, 2024 |
Voting Rights Announcements | 6 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 06. |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 3, 2024 |
Voting Rights Announcements | 3 May 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 03. |
|
| May 3, 2024 |
Voting Rights Announcements | 3 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 03. |
|
| May 3, 2024 |
Voting Rights Announcements | 3 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 03. |
|
| May 3, 2024 |
Voting Rights Announcements | 3 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 03. |
|
| May 2, 2024 |
exhibit991 Voting Rights Announcements | 2 May 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02. |
|
| May 2, 2024 |
exhibit994 Voting Rights Announcements | 2 May 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02. |
|
| May 2, 2024 |
Exhibit (a)(5)(M) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or |
|
| May 2, 2024 |
exhibit993 Voting Rights Announcements | 2 May 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| May 2, 2024 |
Voting Rights Announcements | 2 May 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 30, 2024 |
exhibit991 Voting Rights Announcements | 30 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 30. |
|
| April 30, 2024 |
First Quarter Interim Statement January – March 2024 Contents MorphoSys Group: First Quarter Interim Statement January – March 2024 3 Summary 6 Group Interim Statement 6 Operating Business Performance 14 Human Resources 15 Financial Analysis 24 Subsequent Events 24 Financial Guidance 27 Group Interim Statement 27 Consolidated Statement of Profit or Loss (IFRS) – (unaudited) 28 Consolidated Balance |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 29, 2024 |
exhibit993 Voting Rights Announcements | 29 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 29. |
|
| April 29, 2024 |
Voting Rights Announcements | 29 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 29. |
|
| April 29, 2024 |
Corporate | 29 April 2024 22:01 EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2024 Financial Results 29. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 29, 2024 |
Voting Rights Announcements | 29 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 29. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 26, 2024 |
Voting Rights Announcements | 26 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 26. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 26, 2024 |
Voting Rights Announcements | 26 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 26. |
|
| April 26, 2024 |
Voting Rights Announcements | 26 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 26. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| April 25, 2024 |
Voting Rights Announcements | 25 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 25. |
|
| April 25, 2024 |
Exhibit (a)(5)(L) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 25, 2024 |
Voting Rights Announcements | 25 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 25. |
|
| April 25, 2024 |
Voting Rights Announcements | 25 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 25. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 24, 2024 |
Voting Rights Announcements | 24 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 24. |
|
| April 24, 2024 |
Corporate | 24 April 2024 16:40 EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 23, 2024 |
Voting Rights Announcements | 23 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 23. |
|
| April 23, 2024 |
Voting Rights Announcements | 23 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 23. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 23, 2024 |
Voting Rights Announcements | 23 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 23. |
|
| April 22, 2024 |
exhibit992 Voting Rights Announcements | 22 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 22, 2024 |
exhibit993 Voting Rights Announcements | 22 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. |
|
| April 22, 2024 |
Voting Rights Announcements | 22 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. |
|
| April 22, 2024 |
Voting Rights Announcements | 22 April 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. |
|
| April 22, 2024 |
Voting Rights Announcements | 22 April 2024 16:04 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 22. |
|
| April 19, 2024 |
Voting Rights Announcements | 19 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 19. |
|
| April 19, 2024 |
Voting Rights Announcements | 19 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 19. |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 19, 2024 |
Voting Rights Announcements | 19 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 19. |
|
| April 18, 2024 |
Voting Rights Announcements | 18 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 18. |
|
| April 18, 2024 |
Voting Rights Announcements | 18 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 18. |
|
| April 18, 2024 |
Joint Filing Agreement PURSUANT TO RULE 13d-1(k) Exhibit 1 Joint Filing Agreement PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| April 18, 2024 |
MOR / MorphoSys AG - Depositary Receipt (Common Stock) / NOVARTIS AG - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of Securities) 6177 |
|
| April 18, 2024 |
Exhibit (a)(5)(K) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Sec. |
|
| April 18, 2024 |
Voting Rights Announcements | 18 April 2024 16:02 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 18. |
|
| April 18, 2024 |
6-K 1 a24040186kxmorxvotingrigh.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by c |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MorphoSys AG (Name of Subject Company) MorphoSys AG (Name of Persons Filing Statement) Ordinary Shares, no par value (Title of Class of Securities) 617760202 (CUSIP Number of Class |
|
| April 17, 2024 |
Exhibit (a)(5)(J) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Section 23 para. |
|
| April 17, 2024 |
Exhibit (e)(13) MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Telefon: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 Email: [email protected] Internet: www.morphosys.com Ergänzungsvereinbarung Amendment Agreement zwischen between MorphoSys AG, Semmelweisstr. 7 82152 Planegg („MorphoSys AG“ oder/or die „Gesellschaft“/the “Company”), vertreten durch den Aufsichtsrat, dieser vertreten durch sei |
|
| April 17, 2024 |
Notification of Major Holdings Exhibit (a)(5)(I) Notification of Major Holdings This form is for information purpose only. |
|
| April 16, 2024 |
Voting Rights Announcements | 16 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 16. |
|
| April 16, 2024 |
Voting Rights Announcements | 16 April 2024 16:01 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 16. |
|
| April 16, 2024 |
Exhibit (a)(5)(H) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Section 23 para. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 COMMISSION FILE NUMBER 001-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files o |
|
| April 15, 2024 |
Notification of Major Holdings Exhibit (a)(5)(F) Notification of Major Holdings x Notification of Major Holdings or ¨ Correction of a notification of Major Holdings dated 1. |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) MORPHOSYS AG (Name of Subject Company (Issuer)) NOVARTIS BIDCO AG an indirect wholly owned subsidiary of NOVARTIS AG (Name of Filing Persons (Offerors)) Ordinary Shares, no Par Value (Title of Class of |
|
| April 15, 2024 |
Exhibit (a)(5)(G) – Convenience Translation – (Only the German version is legally binding) Novartis BidCo AG Announcement pursuant to Section 23 para. |
|
| April 12, 2024 |
Voting Rights Announcements | 12 April 2024 16:00 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12. |
|
| April 12, 2024 |
Voting Rights Announcements | 12 April 2024 16:06 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12. |
|
| April 12, 2024 |
Voting Rights Announcements | 12 April 2024 16:05 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12. |
|
| April 12, 2024 |
Voting Rights Announcements | 12 April 2024 16:10 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12. |
|
| April 12, 2024 |
Voting Rights Announcements | 12 April 2024 16:08 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12. |
|
| April 12, 2024 |
Voting Rights Announcements | 12 April 2024 16:03 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12. |
